Pfizer Inc
NYSE:PFE
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
24.5384
31.39
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Pfizer Inc
Revenue Breakdown
Breakdown by Geography
Pfizer Inc
|
Total Revenue:
58.5B
USD
|
|
United States:
27.1B
USD
|
|
Emerging Markets:
12B
USD
|
|
Developed Europe:
11.7B
USD
|
|
Developed Rest Of World:
7.8B
USD
|
Breakdown by Segments
Pfizer Inc
|
Total Revenue:
58.5B
USD
|
|
Biopharma:
57.2B
USD
|
|
Comirnaty Direct Sales And Alliance Revenues:
11.2B
USD
|
|
Eliquis Alliance Revenues And Direct Sales:
6.7B
USD
|
|
Prevnar Family:
6.4B
USD
|
|
Ibrance:
4.8B
USD
|
|
Vyndaqel Family:
3.3B
USD
|
|
All Other Specialty Care:
2.2B
USD
|
|
All Other Primary Care:
1.8B
USD
|
|
Xeljanz:
1.7B
USD
|
|
Business Innovation Segment:
1.3B
USD
|
|
Paxlovid:
1.3B
USD
|
|
Pfizer Centreone:
1.3B
USD
|
|
Xtandi Alliance Revenues:
1.2B
USD
|
|
All Other Anti-Infectives:
1.1B
USD
|
|
Inlyta:
1B
USD
|
|
Nurtec Odt/Vydura:
928m
USD
|
|
Abrysvo:
890m
USD
|
|
Enbrel (Outside The United States And Canada):
830m
USD
|
|
Sulperazon:
757m
USD
|
|
Bosulif:
645m
USD
|
|
Ig Portfolio:
584m
USD
|
|
Genotropin:
539m
USD
|
|
Lorbrena:
539m
USD
|
|
Zavicefta:
511m
USD
|
|
Inflectra:
490m
USD
|
|
All Other Oncology:
433m
USD
|
|
Benefix:
424m
USD
|
|
Zirabev:
424m
USD
|
|
Zithromax:
406m
USD
|
|
Premarin Family:
397m
USD
|
|
Ruxience:
390m
USD
|
|
Xalkori:
374m
USD
|
|
Retacrit:
340m
USD
|
|
Medrol:
339m
USD
|
|
Bmp2:
338m
USD
|
|
Oxbryta:
328m
USD
|
|
Aromasin:
301m
USD
|
|
Fsme-Immun/Ticovac:
268m
USD
|
|
Somavert:
267m
USD
|
|
Fragmin:
238m
USD
|
|
Besponsa:
236m
USD
|
|
Refacto Af/Xyntha:
230m
USD
|
|
Braftovi:
213m
USD
|
|
Cresemba:
195m
USD
|
|
Bavencio Alliance Revenues:
190m
USD
|
|
Vfend:
187m
USD
|
|
Sutent:
180m
USD
|
|
Nimenrix:
179m
USD
|
|
Mektovi:
174m
USD
|
|
Bicillin:
158m
USD
|
|
Cibinqo:
128m
USD
|
|
Trumenba:
126m
USD
|
|
Trazimera:
91m
USD
|
|
Padcev:
52m
USD
|
|
Adcetris:
46m
USD
|
|
Pfizer Ignite:
44m
USD
|
|
Tukysa:
17m
USD
|
|
Tivdak:
4m
USD
|
You don't have any saved screeners yet
